May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Retrospective Study of Macugen Treatment in Naïve Eyes With Age-Related Macular Degeneration
Author Affiliations & Notes
  • E. M. Lad
    Chicago Medical School, North Chicago, Illinois
  • K. A. Rezai
    Ophthalmology, Rush University Medical Center and Illinois Retina Associates, Chicago, Illinois
  • Footnotes
    Commercial Relationships E.M. Lad, None; K.A. Rezai, (OSI) Eyetech, F; (OSI) Eyetech, C; Genentech, C; (OSI) Eyetech, R; Genentech, R.
  • Footnotes
    Support (OSI) Eyetech Pharmaceuticals, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1803. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. M. Lad, K. A. Rezai; Retrospective Study of Macugen Treatment in Naïve Eyes With Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1803. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy of pegaptanib sodium in naïve eyes with wet age related macular degeneration (AMD).

Methods:: Medical charts of 196 patients with wet AMD who were treated with pegaptanib sodium from January 2005 to March of 2006 was retrospectively reviewed. Patients were treated by 11 retina physicians in 10 offices of Illinois Retina Associates. 54 patients were excluded from this study due to previous treatments (laser, kenalog, photodynamic therapy, vitrectomy), lack of fluorescein angiography records, and unclear previous history. 132 patients (85 females, 47 males) with wet AMD who had not received any previous treatment were included in the study. The average age was 81 (range 49-97). The best corrected visual acuity was recorded with the Snellen scale before and after pegaptanib sodium treatment. The recorded Snellen vision was converted to the ETDRS vision and the number of lines gained or lost was calculated.

Results:: The average number of intravitreal pegaptanib sodium injections per patient was 4.23 (range 1-9), for a total of 558 injections in 132 patients. 24 (18.18 %) had a significant improvement in vision (improved ≥ 3 lines), 89 (67.42 %) maintained or improved vision (lost ≤ 0 lines), 111 (84.09 %) did not have a significant vision loss (lost ≤ 3 lines), and 21 (24.49 %) patients had a significant loss of vision (lost more than 3 lines). In patients who received at least 3 intravitreal injections (97 patients), 21 (21.65 %) had a significant improvement in vision (improved ≥ 3 lines), 68 (70.11 %) maintained or improved vision (lost ≤ 0 lines), 83 (85.58 %) did not have a significant vision loss (lost ≤ 3 lines), and 14 (14.43 %) patients had a significant loss of vision (lost more than 3 lines).

Conclusions:: Intravitreal pegaptanib sodium injections stabilized the visual acuity in patients with wet AMD who had not received any previous treatment. A subgroup of these patients showed the tendency of visual improvement after treatment.

Keywords: age-related macular degeneration • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×